Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SATISFY-JP: Satralizumab in Pulmonary Arterial Hypertension in Japan
jRCT2031210626Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of satralizumab in pulmonary arterial hypertension (PAH), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Primary: Percent change in pulmonary vascular resistance at 24 weeks. Started Jul 2022; status: active, not recruiting.
02
Drugs
satralizumab
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on jRCT2031210626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210626.